MAPK10 and lymphoma: Furthermore, our survival analysis revealed that reduced MAPK10 expression in DLBCL is associated with inferior overall survival, particularly pronounced within the ABC subtype (Figures 2C, 5B), positioning MAPK10 as both a potential prognostic biomarker and a promising target for epigenetic therapeutic intervention in the ABC lymphomas.